FLT3 mutations did not have a prognostic impact in patients with AML who had good-risk and poor-risk karyotypes.
In patients with NK-AML, FLT3-ITD mutations led to worse survival, which was even worse among patients who had high mutation burden.
2011-04-27
Eng.
Cancer
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Cancer. 2011 May;117(10):2145-55
© Galenicom 1999-2013